Introduction
Progesterone is one of the key regulators of female reproductive functions, such as uterine and mammary gland development, ovulation,a nd decidualization of the endometrium. During pregnancy,p rogesteronep lays ak ey role in implantation andm yometrial relaxation. Most of the diverse effectso f progesterone on the female reproductive target tissues are mediated via the progesterone receptor (PR). [1] Following the discovery of progesterone in the early 1930s, the identification of syntheticp rogesterone analogues has served as ab asis for the developmentofo ral contraceptives.
In the 1980s, the first PR antagonist, mifepristone (RU 486), was discovered by the French company Roussel-Uclaf. Mifepristone is a1 9-nor-testosterone derivative, which has a4 -(dimethylamino)phenyl group at the 11b-position (see Scheme 1) . The 11b-phenyl group was found to be ac rucial structural element of all potent steroidal PR antagonists. [2] More recently,i t has become evident that mifepristone and other compounds of this structural class can exhibit partial agonistic activity in a species-and tissue-selective manner.
[3] Therefore, these compounds are referred to as selectivePRmodulators (SPRMs).
There is clinicale vidence that the onset and progression of gynecologic disorders/diseases, such as uterinef ibroids, endometriosis and breast cancer, are progesterone-dependent. [4] Therefore, SPRMsa ppear to be ap romising option for the treatment of such diseases.
In addition to its PR antagonistic activity,m ifepristone also showsr elativelys tronga ntagonistic effects towardt he glucocorticoidr eceptor (GR). [5] For long-term application as for the treatment of chronic conditions, improvementi ns electivity is considered to be essential. Therefore, substantial effort has been devoted toward optimizing receptor selectivity of steroidal SPRMs. Several variations of the steroid skeleton have been studied.
Progesterone plays an important role in the femaler eproductive system.H owever,t here is also evidence that gynecologic disorders/diseases such as uterine fibroidsa nd endometriosis are progesterone-dependent. Steroidal and non-steroidal selective progesterone receptor modulators (SPRMs) have shown potentialf or the treatment of such diseases.S teroidal SPRMs, including mifepristone and ulipristal acetate, have provene ffective in clinical trials. However,s everal steroidal SPRMs containing ad imethylamino substituent have been associated with elevated liver enzymes in patients.A ne arlier drug discovery program identified lonaprisan as ah ighly selective SPRM that did not show drug-related change in liver enzyme activity. Buildingo nd ata obtained from that work, here we describe the research program that culminated in the discovery of a novel steroidal SPRM, vilaprisan, whichc ombines an extremely high potencyw ith very favorable drug metabolism andp harmacokinetic properties. Vilaprisan has entered clinical development and is currentlyu ndergoing phase 3c linical trials.
Onapristonei sc haracterized by inversion of stereochemistry at C-13 and C-17 compared with mifepristone, and ar eplacement of the propynyl side chain at C-17 by a3 -hydroxypropyl group (Scheme 1). This compound shows an improved selectivity towarda ntiglucocorticoidal effects. [6] Onapristoned emonstrated efficacy in phase 2c linicalt rials for the treatment of advanced breast cancer.H owever,c linical development was terminated as some patients experienced livere nzyme abnormalities.
[4f] Elevated levels of liver enzymes have also been observed for mifepristone, ulipristal acetate and proellex (CDB-4124).
[7] All of these compounds have the 4-(dimethylamino)-phenylg roup in common. This structurale lementi sa ccessible to metabolic demethylations, which may lead to the formation of aniline metabolites that have been reported to cause undesired effects in the liver by the formation of reactive intermediates. [8] The hitherto available data from clinicals tudies with SPRMs lacking the dimethylamino phenylg roup, for example, lonaprisan, have provided no evidence of ac linically relevant, drug-related change in liver enzyme activity.
Investigations have shown that replacement of the dimethylamino group by an acetyl group was tolerated without losing efficacy.H owever,t he 17a side chain was identified as the key factor for selectivity toward other nuclear hormone receptors. This position was therefore chosen for ad etailed structure-activity relationship (SAR) analysist oh elp identify highly potent SPRMs with further decreased endocrine side effects. As a result of an intensive discoveryp rogram, lonaprisan (BAY 865044/ZK 230211), which exhibits au nique potency and selectivity,w as identified in the late 1990s. Lonaprisan has a4 -acetylphenyl substituent at C-11a nd ap entafluoroethyl group as an ew 17a side chain (Scheme 1). [9] The compound has demonstrated much stronger antiproliferative activity [10] than mifepristone and onapristone in hormone-dependent in vitro systems. Lonaprisanh as also shown superior antitumor activity in an umber of preclinical in vivo models compared with mifepristonea nd onapristone. [11] In two randomized,p lacebo-controlled, phase 1s tudies in healthy postmenopausal women,l onaprisan was well tolerated without any sign of elevated liver enzymel evels, indicating that potentialh epatotoxicity was not ac oncern with this drug. [12] The efficacyo fl onaprisan as second-line endocrine therapyw as evaluated in ar andomized, phase 2s tudy of postmenopausal women with stage IV,P Rpositive metastatic breast cancer. Although disease stabilization was observed in some patients for ac linically useful period, the study did not meet its primary endpoint and was therefore terminated. [13] The failure of lonaprisan in this clinical oncology trial was a seriouss etback for the compound class of steroidal SPRMsf or the treatment of hormone-dependent cancer.H owever,t he potentialo fs teroidal SPRMs for the treatment of uterine fibroids and endometriosis has been demonstrated in several clinical trials with different compounds, including mifepristone, ulipristala cetate, asoprisnil, and proellex (CDB-4124). Development work on thesea nd other steroidal SPRMs, both for clinical indications and as discoveryl eads, hasc ontinued. Ulipristal acetate (ESMYA TM ), for example, is now indicated for pre-surgical treatment and repeated intermittent treatment of uterine fibroids in the EU and several other countries. [14] Lonaprisan was also considered to be ap otentialc andidate for gynecologic indications, due to its very high potencyi n combination with its favorable selectivity profile. Three major metabolites of lonaprisan formed by the biodegradation of the 4-acetyl group were identified in human plasma.T hese metabolites significantly contribute to the overall activity of the drug candidate (Table 1) , as measuredb yr eceptor transactivation assays. The presenceo fp harmacodynamically active metabolites-in particular,t hose with long half-lives and thus prolongedc irculation in vivo-is considered to be disadvantageous in intermittent treatment regimens.S uch intermittent treatment regimens are currently being developedf or SPRMs in long-term use. [15] Accordingly,l onaprisan is not considered to be an ideal candidate for the treatmento fu terinef ibroids and endometriosis. On the other hand, the surprisingly high potencyo fs ome of the metabolites-in particular, compound 1-showed that higher polarity is tolerated at the 4-position of the 11b-phenyl group than originally anticipated. Furthermore, the lonaprisan metabolite 1 was found to be about seven times less potent than the parent compound in transactivationa ssays,a lthough only at hreefold higherd ose wasr equired for early pregnancy termination tests in rats to achieve as imilar efficacy as observed for lonaprisan. This indicates an improved oral bioavailability due to the more favorable physicochemical properties of metabolite 1 (compound 1 exhibits a1 0-foldh ighera queous solubility compared with the parent compound lonaprisan).
Based on theser esults, an ew drug discoveryp rogram was initiated aiming to identify compounds with potencya nd selectivity similar to those of lonaprisan, but with higher metabolic stability to avoid the formation of active circulating metabolites.
Results and Discussion

Discovery of vilaprisan
Because the 17a-pentafluoroethyl group demonstrated af avorable selectivity profile, this position was left unchanged. Instead, the new program focused on modificationso ft he 4-substituent attached to the 11b-phenyl ring, which wasf ound to be metabolically unstable in lonaprisan. Broad modifications of position1 7h ave been described in the literature ande ven the steroids keleton has been reported with severalv ariations, [6, 16] whereas only ar elatively low number of 4-substituents have been characterizedi nd etail. Until the start of our new program, only three different substituents at the 4-position of the 11b-phenyl ring had been included in the structure of clinical candidates. Excluding lonaprisan (4-acetyl) anda soprisnil (4-hydroxyiminomethyl), another representative of this compound class, [16] all other SPRMst hat entered clinicalt rials carried the 4-dimethylaminog roup. Our new study included the investigation of ab road range of other groups of compounds.B eyond the variation of 4-substituent of the 11b-phenylr ing described in this paper,w ea lso explored the influence of substituents at other positions of the phenylr ing including disubstitutedc ompounds. All thesed erivatives were found to be not superiorc ompared with the para-substituted derivatives.
The new derivatives were tested for their PR antagonistic activity in vitro using transactivation assays.However,potency indicatedi nt ransactivation assays cannot be directly translated to in vivo efficacy without consideration of the absorption, distribution,m etabolism, excretionp roperties that are relevant to achievethe required exposure of the compound in vivo. Therefore, we decided to consider all compounds for in vivo characterization in ap harmacologica nimal model,w hich had both an IC 50 value of 0.5 nm or lower and showed sufficient in vitro metabolic stabilityw hen tested in human and rat liver microsomes.
As shown in Ta ble 2, initially the 4-unsubstituted derivative 4 was synthesized and characterizedi nv itro. This compound was found to be relativelyp otent in vitro (IC 50 = 0.17 nm), but interestingly showedo nly 90 %e fficacy.E arlier observations from our previous program (unpublished results) indicated that full inhibitory efficacy was required in the transactivation assay for compounds to show antagonistice ffects in vivo. Compounds that reached only 90 %a ntagonistic efficacy in vitro were found to be full PR agonists in vivo.
Introduction of av inyl group at the 4-position (compound 5)l ed to almostc omplete antagonistic efficacy and as ignificant improvement in potency compared with the unsubstituted derivative(compound 4).
Af urther increase of the size of the 4-substituent resultedi n some compounds, such as derivatives 6-8,t hat exhibited full antagonistic efficacy in vitro. However,a st hese derivatives showedl ower metabolic stability in liver microsomes, they were not tested furtherinv ivo.
The pharmacologic activity determined for the lonaprisan metabolites showed that ac ertain polarity was tolerated at the 4-position. Thus, several functional groups were introduced at different distances to the steroids keleton to systematically explore the SAR. Derivatives with hydroxy groups,s uch as the lonaprisan metabolite 2,i ng eneral exhibitedh ighp otency (Table 1) . However,o nly low metabolic stability was observed for these compounds.
Introduction of ac arboxylic acid functiona tt he same position (compound 9)l ed to an almostc omplete loss of activity. Additiono facarboxylic acid was further studied by the introductiono fabroad range of spacers of different lengthsb etween the carboxy group and the 11b-phenyl group, such as in compounds 10 and 11.T hese compounds yielded variable results.F or example, the acid 10 did not show any improvement in potency.B yc ontrast, the biphenyl derivative 11 was unexpectedly found to be very potent. In addition, compound 11 exhibited very high metabolic stability in both rat and human liver microsomes. Therefore, this compound was selected for in vivo characterization.
Replacement of the carboxylic acid in compound 9 by small amides led to an improvement in potency (for example, in compounds 12 and 13), showing IC 50 values of around1n m, although they did not reach the IC 50 values of the most potent derivatives. To further explore the SAR of amide derivatives, we synthesized al ibrary of such compounds, including examples with one or more additional functional groups in the amino part. Some of these more complex amides showedi mprovementsi np otency,b ut none of them could fulfill the desired profilet oq ualify them for an in-depthc haracterization due to, for example, poor metabolic stability.
The dimethylamino group at position4of the phenylr ing, originally discovered in mifepristone, is one of the most prominent substituents for SPRMsa tt his position.T his functional group is metabolized to aniline-like derivatives which may be responsible for the hepatotoxicity observed in humans at higherd oses with various SPRMs.
[4f, 7, 8] Accordingly,o ptions to shift the amino functiona way from the phenylr ing to avoid the metabolic formationo fa niline derivativesw ere evaluated and al ibrary of such compounds was generated by parallel synthesis. The potency of these compounds was compared Table 3 . Surprisingly,a nd in contrast to others eries with different 17-substituents than pentafluoroethyl, it was observed that replacemento ft he acetyl group in lonaprisanb yad imethylamino function led to a2 5-fold decreasei np otency.I ntroduction of am ethylene group between the dimethylamino group and the phenyl group (compound 15)l ed to af urther decrease in potencyb yafactor of more than 15. Compound 16,w ith a methyl piperazine at the benzylic position, and several other derivativest hat are not shown here, exhibited potencies that did not qualify them fori nv ivo characterization. Other compounds in this series exhibited an improvement in potency withouto vercoming the unfavorable pharmacokinetic (PK) properties.
Derivatives with sulfur-containing substituents at the 4-position of the 11b-phenyl ring were also synthesized,t hree of [18] ). Accordingly,t his derivativew as also selected for furtheri nv ivo characterization. Other sulfur-containing derivatives (not shown) exhibitedp roperties that made them unsuitable for furtherc haracterization, fore xample, inefficient potency,l ow metabolic stabilityo ri ncreased lipophilicity.
Compounds 1 (metabolite of lonaprisan), 11, 18 (vilaprisan) and 19 were studied in an early pregnancy test in rats (Table 4) , which is as uitable in vivo modelt op redict PR antagonistic activity. [9] Progesterone is essential for an undisturbed pregnancy in mammals. This biologicp rinciple can be used to determine PR antagonistica ctivity of ac ompound. In this regard, aP Ra ntagonist competitively blocks the PR in the endometrium, which finally leads to the interruption of an ongoing pregnancy.
Besides maintenanceo fp regnancy,p rogesterone is responsible for the glandular differentiation and secretory transformation of the endometrium. These actionso fp rogesterone were assessed in juvenile rabbits using the McPhail test,t oe valuate PR agonistic and antagonistic effects. [9] Priming of the rabbit endometrium with 17b-estradiol followed by the administration of aP Ra gonistl ed to an induction of glandular differentiation.T he degree of glandulard ifferentiation was determined by light microscopy (rating grades 1-4;1= no glandulard ifferentiation, 4 = maximal differentiation). Therefore, after priming with 17b-estradiol, rabbits were either treated with the test compounds alone to show potential PR agonistic effects, or togetherw ith the naturalh ormone progesteronet ot est the PR antagonistic effects (inhibition of differentiation induced by progesterone). Only al imited number of test compounds that showedf avorable PK properties and activity in the early pregnancy test in rats were tested in the McPhail test.
In the early pregnancy test, all compounds were administered orally except for compound 11 (whichw as given subcutaneously). The doses and corresponding exposures (area under the curve [AUC]) required to achievef ull efficacy were compared with that of lonaprisan (Table 4) . Compound 1 was found to required oses approximately three times higherc ompared with vilaprisan to reach full efficacy in this experiment (1.5 mg kg À1 comparedw ith0 .5 mg kg À1 ), whereas compounds 11, 18 (vilaprisan) and 19 required similar doses to lonaprisan (0.5 mg kg À1 ). Sulfoximine 19 was partly converted into sulfone vilaprisan (18)i nv ivo, comprising one-third of the total exposure of the parent compound. This finding suggests that after administration of sulfoximine 19,v ilaprisan contributes significantly to the pharmacologic effect due to its 10-foldhigherpotency.A ccordingly,c ompound 19 is considered to exert its high activity,atl east in part, as ap rodrug of vilaprisan (18) .
Compounds 1, 11 and 18 (vilaprisan) were also tested in the endometrial transformation assayi nr abbits ( Table 4) . Compound 1 againd emonstrated approximately three times lower potencyt han lonaprisan, whereas vilaprisan (18)a nd the biphenylcarboxylic acid 11 were shownt obeaspotentaslonaprisan. Based on the in vivo results described, vilaprisan (18) and the biphenylcarboxylic acid 11 were selected as the most promising follow-up candidates.
Prediction of human exposure-efficacy and dose
For the two compounds 11 and 18 (vilaprisan), the prediction of the efficacious human dose was performed based on the predicted human PK and the exposure-efficacy relationship establishedi nt he animal models, confirming exposure (AUC) as the driver of efficacy.T he data were corrected by plasma protein binding in human and animal species. For vilaprisan (18) , prediction of human PK was performed by as ingles pecies scaling approach using the in vivo clearance obtained from cynomolgus monkeys extrapolated to humans on ab ody weightb asis. The efficacious exposure during the 24 hd osing intervala ts teady state [AUC(0-24h) ss ]i nt he rat and rabbit modelsw as 116 mg hL À1 and1 26 mg hL
À1
,r espectively, translating into ap redicted efficacious human daily oral dose of 2.5 mg, considering free fraction in human, rat and rabbit plasma of 5% in all species. For compound 11,p rediction of human PK was performed by as ingles pecies scaling using in vivo clearance from the rat combined with ad irect scalinga pproach using in vitro clearance from rat and human liver microsomes. Considering free fractionso f0 .6 %i nh uman plasma and 0.7 %i nr at plasma and the efficacious AUC(0-24h) ss in rats of 573 mg hL
,this translated into apredicted efficacious humand aily oral dose of 11 mg. The significantly lower human daily dose predicted for vilaprisan (18)c ompared with compound 11 supported the selection of vilaprisan (18)a sacandidate for further development. Ac omparison of vilaprisan (18)w ith the previousc linicalc andidate lonaprisan in terms of drug metabolism and PK in humans is briefly summarized below.
Drug metabolism and pharmacokinetics in humans
In vitro and in vivo experiments show that lonaprisan is rapidly metabolized, with the formation of three major metabolites (compounds 1, 2, 3)i nh uman plasma (see Table 1 ). They are formed by the biodegradation of the 4-acetyl group. The exposure in terms of AUC of each of these metabolites significantly exceeded the AUC of the parent compound lonaprisan( see Ta ble 5). The IC 50 values of compounds 1 and 2 (see Table 1 ) in the in vitro transactivation assay were only 5-7-fold higher compared with the parentc ompound lonaprisan. Compounds 1 and 2 were therefore expectedt os ignificantly contribute to the pharmacologic activity of the drug candidate in humans. The metabolite compound 1 was also found to be highly active in both in vivo models(see Ta ble 4).
In contrast, the unchanged parent compound vilaprisan (compound 18)w as the main component in human plasma. [17] Only af ew minor metabolites formed by the reduction and oxidation of the steroids keleton were identified in human plasma,e ach not exceeding1 0% of the AUC of total drug-related compounds. This was ac onsequence of the modification of the 4-substituent at the 11b-position, as the 4-sulfonyl group in vilaprisan was not metabolized.V ilaprisan was metabolized by oxidation reactions at different positions of the steroid skeleton and reduction of the carbonyl group in the 3-position, as well as ac ombination of both modifications. The two distinct metabolites of vilaprisan that were identified in human plasma were formed by reduction in the 3-position (compound 20)a nd by the combination of reduction and oxidation (compound 21)( see Scheme 2) . The AUC of these two metabolites after multiple oral administrations of 5mgv ilaprisan exhibited approximately 20 %o ft he AUC of unchanged vilaprisan (see Ta ble 5 ). The metabolites 20 and 21 showeda pproximately a factor of 60 (compound 20)a nd af actor > 6700 (compound 21)l ower potencyi nv itro in the transactivation assay.C onsidering the relatively lowp otencyo ft he two metabolites and the low fraction in exposure compared with vilaprisan in humans, [17] neither metabolite contributes to the in vivo activity of vilaprisan.
Syntheses
The synthesis of lonaprisan was described previously. [9] Key steps in the synthetic route are the introductiono ft he 11b-substituent in ac opper-catalyzed Grignardr eaction and the introduction of the 17a-(pentafluoroethyl) group in am odified Gassman procedure. [19] The principalf ocus of the current drug discoveryp roject was the systematic modification of the 11b-substituent. Therefore, the order of the reactions was modifiedb yi ntroducing the 17a side chain prior to the 11b-substituent. Thiss trategy allowed an efficient and broad modificationo ft he 11b-substituenta tt he end of the sequence. Only the lonaprisan metabolite 2 was synthesized following the original sequence using am odified buildingb lock for the introduction of the 11b-phenyl group. Introduction of the 17a-pentafluoro ethyl group [19] into the previously published intermediate 22 [20] yielded compound 23,w hich was used for the introduction of the 11b phenyl group. With one exception (the introductiono ft he oxetane building block in compound 8 required specialr eaction conditions, as outlined in the Supporting Information), all other1 1 b-substituents werei ntroducedi nac opper-catalyzed Grignardr eaction, leading to the intermediates 24 a-l as showni nS cheme 3. In some cases, the 4-substituentY ' was already the final group Y, whereas in other cases additional reactions weren eeded to build up the final substituent. The derivatives 1, 3, 4, 5, 6, 8, 14 and 17 were preparedd irectly from the intermediates (24 a-e, 24 j, 24 k, 24 l)b ya na cidic cleavage of the protecting group(s)a nd concomitant elimination of the 5a-hydroxy group.
As shown in Scheme 4, the synthesis of compounds 7, 9, 10, 12, 13, 15, 16 and 18 required additional modification of the 4-substituent. Cyclopropanation of intermediate 24 d yielded compound 25,w hichw as transferred to compound 7 by acidic cleavage of the protecting group. Acidic deprotection of intermediate 24 f produced 26,w hich was used for the preparation of the carboxylic acid 9.A mide formationo f9 under standard conditions produced the dimethylamide 13.C leavage of the The sulfoximine 19 as mixtureo fe pimers was synthesized according to Scheme 6. Treatment of intermediate 24 k with chloramine-T trihydrate yieldedc ompound 36,which was oxidized to 37 by treatment with hydrogen peroxide. Cleavage of the ketal under standard conditions gave compound 38.T he releaseo ft he sulfoximine 19 required stronger acidic conditions and was achieved by treatment with concentrated sulfuric acid. 
Conclusions
The first SPRMs becamea vailablem ore than 25 years ago. Historically,t his compound class has been considered for a number of indications with high unmet medical need, such as uterinef ibroids and endometriosis. The chronic nature of these conditions implicates the requirement for long-term medical treatment. However,t he first SPRMs demonstrated relatively strong GR antagonistics ide effects and therefore were not considered to be appropriate for long-term application.T he SPRM onapristone that succeeded in the development, failed in clinical trials due to unexpected liver intolerance with longterm use. Later,the SPRM lonaprisan was discovered, which exhibited afavorable selectivity profile and was tolerated without any signs of liver toxicity. However,i nvestigationsi nto its use in the treatment of metastatic breast cancer failed as it did not reach its primary clinical endpoint. In clinicalt rials, it was found that lonaprisan formed ac ocktailo fa ctive metabolites that significantly contributed to its overall activity.T herefore, the compound was considered suboptimal for gynecologic indications.
Here, we describe ad rug discovery program that focusedo n the improvement of the PK properties of lonaprisan. Extensive modifications were attempted to stabilizet he 4-substituent of the 11b-phenyl ring while maintaining the favorable potency, selectivity and safety profile of formerc andidates. Several potent derivatives were identifieda nd comprehensive characterization of the new derivatives in vitro and, for the most promisingc ompounds, then in vivo, led to the discovery of vilaprisan. This compound combines an extremely high selectivity towardt he PR compared with other nuclear receptors [8d] with favorable tolerability,and significantly improved PK profile compared with lonaprisan. After successful profiling in preclinical development, investigations of the compound have progressedtoclinical trials, and phase 1 [21, 22] and phase 2 [23] clinical trials have been completed. Recently,t he compound entered phase 3c linical developmentt oe xamine the efficacy and safety of vilaprisan in the treatment of symptomsa ssociated with uterinef ibroids-measured by decreases in heavy menstrual bleeding, reductions in fibroid size, and improvements in health-related quality of life of patients.A dditionally,a phase 2b studyf or the treatment of women sufferingf rom endometriosis has been initiated.
Herein we have described ar esearch program that culminated in the discovery of an ovel SPRM with af avorable safety profile and improved PK properties. Based on its high potency, high selectivity for the PR, and PK with absence of biologically active metabolites,v ilaprisan represents aS PRM optimized for long-term, intermittent clinicalu se in pre-menopausal women.
Experimental Section
Chemistry Materials and methods:A ll commercially available starting materials and solvents were purchased and used without further purification. Flash column chromatography was performed using prepacked flash chromatography columns PF-15-SIHP purchased from Interchim or KP-Sil purchased from Biotage using aB iotage Isolera separation system. 1 HNMR spectra were recorded at room temperature on Bruker Avances pectrometers operating at 300 or 400 MHz. NMR signal multiplicities are reported as they appeared, without considering higher-order effects. Chemical shifts (d)a re given in parts per million (ppm) with the residual solvent signal used as ar eference (CDCl 3 :s inglet [s],7 .26 ppm;[ D6]DMSO:q uintet, 2.50 ppm). Liquid chromatography mass spectrometry (LC-MS) spectra were recorded on aW aters Acquity ultra performance liquid chromatography (UPLC)-MS SQD 3001 spectrometer,u sing an Acquity UPLC BEH C18 1.7 50 2.1 mm column, with acetonitrile and water + 0.1 %f ormic acid as eluents at 60 8C, af low rate of 0.8 mL min À1 ,a ni njection volume of 2 mL, with diode-array detector scan at 210-400 nm, ELSD. All tested compounds were at least 95 %pure, as determined by 1 HNMR spectroscopy. (50 g, 134.2 mmol, synthesis described previously [20] )i n5 00 mL dry toluene was added at À70 8C. A1 .5 m solution of methyllithium-lithium bromide complex in diethyl ether (290 mL, 435 mmol) was added slowly at À70 8C. Afterward, it was stirred for 1h at 0 8C. The reaction mixture was then poured into saturated aqueous ammonium chloride solution. The aqueous layer was extracted with ethyl acetate three times. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and evaporated. The crude product was dissolved in 80 mL toluene (at 70 8C). This was then diluted with 250 mL hexane. The resultant suspension was stirred for 1h at 0 8Ca nd was then filtered and dried in vacuo. The obtained product (51.57 g, 104.7 mmol, 78 %y ield) was used without further purification. 2) General procedure for the introduction of the 11b-phenyl substituent (derivatives 24a-24k):D ibromomethane (5 mL) was added to 5mmol magnesium turnings in 0.5 mL dry tetrahydrofuran (to activate the magnesium turnings). As olution of the bromophenyl building block (5.1 mmol) in 6mLd ry tetrahydrofuran was added to this suspension slowly so that the reaction temperature did not exceed 55 8C. The solution was then stirred for 1h.A fter stirring, the reaction mixture was cooled to 0 8Ca nd 0.15 mmol copper(I) chloride was added. Stirring was continued for an additional 15 minutes. Afterward, as olution of 1mmol of compound 23 in 5mLd ry tetrahydrofuran was added at 0 8C. The reaction mixture was allowed to warm up to 23 8Co ver a3hp eriod and stirred for additional 10 ha tt his temperature. The reaction mixture was then poured into ice-cold saturated aqueous ammonium chloride solution. After stirring for 30 minutes, it was extracted with ethyl acetate three times. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and evaporated. The crude product was purified by chromatography over silica gel using hexane/ethyl acetate.
3) General procedure for the cleavage of the protecting groups in the final step under acidic conditions:
ChemMedChem 2018, 13,2271 -2280 www.chemmedchem.org 2018 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim a) Using hydrochloric acid (applied for the preparation of compounds 5-8):0 .14 mmol of the protected precursor was dissolved in 5mLa cetone. Hydrochloric acid (0.7 mL, 4 n)w as added and the reaction mixture was stirred for 1h at 25 8C. The reaction mixture was then poured into saturated aqueous sodium hydrogen carbonate solution. It was extracted with ethyl acetate. The organic layers were washed with brine and the crude product was purified by column chromatography. b) Using diluted sulfuric acid (applied for the preparation of compounds 1, 2, 3, 4, 12, 14, 17):0.43 mmol of the protected precursor was dissolved in 5mLm ethanol. Aqueous sulfuric acid (5 mL, 50 %) was added. The reaction mixture was stirred for 2.5 h at 25 8C. The reaction mixture was then poured into saturated aqueous sodium hydrogen carbonate solution. It was extracted with ethyl acetate. The organic layers were washed with brine and the crude product was purified by column chromatography. c) Using acetic acid (applied for the preparation of compound 11):0 .51 mmol of the protected precursor was dissolved in acetic acid (3 mL, 70 %). The reaction mixture was stirred for 2h at 25 8C and for another 2.5 ha t3 5 8C. The reaction mixture was then poured into ice water and stirred for 2h.T he formed precipitate was filtered and purified by column chromatography. Compound 24 k( 5g,8 .1 mmol) was dissolved in am ixture of 140 mL tetrahydrofuran and 140 mL methanol. The reaction flask was put in an ice bath. As olution of 20 gO xone in 94 mL water was slowly added (the temperature inside the flask increased up to 12 8C). The reaction mixture was kept in the ice bath and stirred for 3.5 h. It was then diluted with water and dichloromethane. The phases were separated and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine and the crude product was purified by column chromatography.T he product (3.8 g, 86 %) was obtained as aw hite solid. 
In vivo assays
Animals:R ats and rabbits were obtained from Charles River (Germany). Wistar rats (100-230 g) and New Zealand white rabbits (35-42 days old, 900-1300 g) had access to food and water ad libitum. All animals were housed according to institutional guidelines at a 12 h/12 hl ight-dark cycle. Rats were maintained under standard conditions (20-22 8C; 50-70 %h umidity). The rats were housed in Makrolon cages type IV,f ive animals per cage, and fed ap elleted diet (Sniff, Germany). Rabbits were kept at 19 AE 1 8Ca nd 35-65 % humidity.T hey were conventionally housed in air-conditioned rooms in Scanbur cages (standard I) and fed Altromin 2023 diet (Altromin, Germany). All animal studies were performed according to the German Animal Welfare Act and were approved by the competent regional authorities. All animal studies were performed in accordance with the ethical guidelines of Bayer AG.
Test for PR activity during early pregnancy (rat) and endometrial transformation (rabbit):T he early pregnancy test was carried out as described previously. [9, 20] In brief, 5-7 days post-coitum, rats (n = 6) were randomized to receive the test compound in different doses (s.c. or p.o.) or vehicle (benzylbenzoate/castor oil;1+ 4 v/v, respectively 85 mg polyoxyethylene-(50)-stearate in 100 mL 0.9 % w/v NaCl). Autopsy was performed on Day 9; the absence of implantation sites was assessed as complete interruption of pregnancy and the presence of regressed and/or hemorrhagic implantation sites were defined as pathologic nidation sites. Full efficacy in termination of early pregnancy studies indicated that all animals of the corresponding dose group lacked implantations or had pathologic nidation sites.
PR activities of the test compounds on endometrial glands were tested in juvenile rabbits (900-1300 g). From Days 1t o4 ,r abbits were primed with 5.0 mg kg À1 day À1 17b-estradiol (s.c.). In order to test the anti-progestational activity,a nimals were randomized (n = 4) to receive 0.2 mg kg À1 day À1 progesterone (s.c.) and the test compound (p.o.) from Days 7t o1 0. Progestogenic activity was tested by the test compound (p.o.) alone. Autopsy was performed on Day 11.A st he parameter for progestogenic (induction of glandular differentiation) or anti-progestational activities (inhibition of induction of glandular differentiation), the McPhail index (degree of glandular differentiation) was determined by light microscopy (rating grades 1-4;1 = no glandular differentiation, 4 = maximal differentiation). Full efficacy in endometrial transformation studies indicated that the degree of glandular differentiation in all animals of the corresponding dose group was characterized by aM cPhail index of 1o r1 .5.
Drug metabolism and pharmacokinetics
Metabolic stability in liver microsomes:T he compounds were incubated in human or rat liver microsome suspensions at af inal concentration of 0.3-3 mm.T he incubations were stopped after 1h and analyzed by high-performance liquid chromatography using MS/MS or ultraviolet detection to determine the rate of degradation. This provided the in vitro intrinsic clearance according to Lau et al. [24] based on the amount of microsomal protein and specific liver weight. Predicted in vivo clearance (CL H )w as calculated based on the "well-stirred" liver model based on rat or human liver blood flow (Q H )r esulting in the hepatic extraction ratio E H according to E H = CL H /Q H .M aximum bioavailability (F max [%]) was calculated from the calculated extraction ratio according to: F max [%] = 1ÀE H assuming 100 %absorption.
Plasma protein binding:D etermination of plasma protein binding of test compounds in human and animal plasma was performed according to Schuhmacher et al. [25] Determination of metabolites of lonaprisan in human serum: Human serum samples were obtained from volunteers after single oral administration of 200 mg lonaprisan (clinical study ME301781). The concentration-time profiles of the three metabolites (compounds 1, 2 and 3)a nd lonaprisan were determined by an LC-MS/ MS method with external calibration using authentic reference compounds. The PK parameters of lonaprisan and compounds 1, 2 and 3 were calculated by appropriate methods. The product of hydroxylation and reduction in the 11b-position (compound 3)i st he major metabolite of lonaprisan in human serum (AUC = 57 %o f sum of drug-related compounds or 920 %o fA UC of lonaprisan). The exposures of compound 1 (hydroxylation) and compound 2 (reduction) and lonaprisan were found to be 18 %, 19 %a nd 6% of sum of drug-related compounds, respectively.A ccordingly,c ompound 1 and compound 2 exhibited 285 %a nd 312 %o ft he AUC of lonaprisan.
Determination of the metabolites of vilaprisan in human plasma:T he exposure of metabolites of vilaprisan (compound 18) in human plasma was investigated following multiple oral administration of 5mgv ilaprisan in healthy volunteers. The concentration-time profiles and the AUC of the two metabolites (compounds 20, 21)a nd vilaprisan were determined by aL C-MS/MS method with external calibration using authentic reference compounds. The PK parameters of vilaprisan and compounds 21 and 22 were calculated by appropriate methods. The parent compound vilaprisan accounted for the major part of the total drug-related components in human plasma [AUC(0-24 h) ss % 438 mg hL À1 at steady state after daily oral administration of 5mg].
Metabolite 20,f ormed by reduction of the 3-keto group resulting in formation of the 3a-hydroxy derivative, accounted for an AUC(0-24 h) ss % 97.8 mg hL À1 at steady state after daily oral administration of 5mgv ilaprisan corresponding to 22.3 %o ft he AUC(0-24 h) ss of unchanged vilaprisan. Metabolite 21,f ormed by reduction at the 3-keto group and oxidation, accounted for an AUC(0-24 h) ss % 77.1 mg hL À1 at steady state after daily oral administration of 5mgv ilaprisan corresponding to 17.6 %o fA UC(0-24 h) ss of unchanged vilaprisan.
